Difference between revisions of "ALK translocation renal cell carcinoma"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 17: | Line 17: | ||
==IHC== | ==IHC== | ||
*ALK +ve. | *ALK +ve. | ||
*[[SMARCB1]] | *[[SMARCB1]] +ve.{{fact}} | ||
==See also== | ==See also== | ||
Revision as of 18:00, 17 March 2019
ALK translocation renal cell carcinoma is a proposed entity within the Vancouver modification of the 2004 WHO classification of renal neoplasia.[1]
General
- Extremely rare.
- May be related to renal medullary carcinoma which is reported to have an ALK rearrangement - t(2;10)(p23;q22).[2]
- May respond to ALK inhibitors, e.g. Alectinib.[3]
Microscopic
Features:
- Mix of morphologies - including rhabdoid change, sarcomatoid change, "unclassified renal cell carcinoma", papillary renal cell carcinoma.
DDx:
IHC
- ALK +ve.
- SMARCB1 +ve.[citation needed]
See also
References
- ↑ Srigley, JR.; Delahunt, B.; Eble, JN.; Egevad, L.; Epstein, JI.; Grignon, D.; Hes, O.; Moch, H. et al. (Oct 2013). "The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.". Am J Surg Pathol 37 (10): 1469-89. doi:10.1097/PAS.0b013e318299f2d1. PMID 24025519.
- ↑ Mariño-Enríquez, A.; Ou, WB.; Weldon, CB.; Fletcher, JA.; Pérez-Atayde, AR. (Mar 2011). "ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.". Genes Chromosomes Cancer 50 (3): 146-53. doi:10.1002/gcc.20839. PMID 21213368.
- ↑ 3.0 3.1 Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.